TNFSF11 and rheumatoid arthritis: Targeting osteoclasts using denosumab, an anti-RANKL antibody, shows efficacy on the progression of arthritic bone erosion without affecting RA disease activity39,40, emphasizing the importance of osteoclasts in arthritic bone erosion.